ATE78162T1 - 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. - Google Patents

5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.

Info

Publication number
ATE78162T1
ATE78162T1 AT88909596T AT88909596T ATE78162T1 AT E78162 T1 ATE78162 T1 AT E78162T1 AT 88909596 T AT88909596 T AT 88909596T AT 88909596 T AT88909596 T AT 88909596T AT E78162 T1 ATE78162 T1 AT E78162T1
Authority
AT
Austria
Prior art keywords
treatment
bronchoconstriction
cough
pct
receptor antagonists
Prior art date
Application number
AT88909596T
Other languages
English (en)
Inventor
Andrew James Beecham Williams
Road Bottom
Original Assignee
Beecham Group Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB878726716A external-priority patent/GB8726716D0/en
Priority claimed from GB878726717A external-priority patent/GB8726717D0/en
Application filed by Beecham Group Plc filed Critical Beecham Group Plc
Application granted granted Critical
Publication of ATE78162T1 publication Critical patent/ATE78162T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Electrotherapy Devices (AREA)
  • Conductive Materials (AREA)
  • Peptides Or Proteins (AREA)
  • Indole Compounds (AREA)
AT88909596T 1987-11-14 1988-11-14 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion. ATE78162T1 (de)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB878726716A GB8726716D0 (en) 1987-11-14 1987-11-14 Treatment
GB878726717A GB8726717D0 (en) 1987-11-14 1987-11-14 Treatment
PCT/GB1988/000994 WO1989004660A1 (en) 1987-11-14 1988-11-14 5-ht3 receptor antagonists for treatment of cough and bronchoconstriction
EP88909596A EP0340270B1 (de) 1987-11-14 1988-11-14 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion

Publications (1)

Publication Number Publication Date
ATE78162T1 true ATE78162T1 (de) 1992-08-15

Family

ID=26293045

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88909596T ATE78162T1 (de) 1987-11-14 1988-11-14 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.

Country Status (9)

Country Link
US (1) US5098909A (de)
EP (1) EP0340270B1 (de)
JP (1) JPH02502185A (de)
KR (1) KR890701099A (de)
AT (1) ATE78162T1 (de)
AU (1) AU616706B2 (de)
DE (1) DE3872872T2 (de)
DK (1) DK345889A (de)
WO (1) WO1989004660A1 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU8072691A (en) * 1990-06-28 1992-01-23 Beecham Group Plc Pharmaceutical preparations
HU211081B (en) * 1990-12-18 1995-10-30 Sandoz Ag Process for producing indole derivatives as serotonin antagonists and pharmaceutical compositions containing the same
WO1993000074A1 (en) * 1991-06-26 1993-01-07 Sepracor, Inc. Method and compositions for treating emesis, nausea and other disorders using optically pure r(+) ondansetron
WO2000051582A2 (en) 1999-03-01 2000-09-08 Sepracor Inc. Methods for treating apnea and apnea disorders using optically pure r(+)ondansetron
CN1355698A (zh) * 1999-06-15 2002-06-26 呼吸器有限公司 可用作治疗有关支气管收缩的机能障碍的药物的化合物
GB9918425D0 (en) * 1999-08-04 1999-10-06 Novartis Ag Organic compounds
WO2001095903A1 (en) * 2000-06-15 2001-12-20 Respiratorius Ab 5-ht3 receptor antagonists for treatment of disorders involving airway constriction
CA2499128C (en) * 2002-09-25 2012-07-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
WO2004091606A1 (en) * 2003-04-16 2004-10-28 Orchid Chemicals & Pharmaceuticals, Ltd. Treatment of bronchial asthma using 5-ht3 receptor antagonists
PL1697378T3 (pl) * 2003-12-22 2008-04-30 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzoizoksazole i 1,2-benzoizotiazole oraz ich wytwarzanie i zastosowania
WO2005092890A2 (en) 2004-03-25 2005-10-06 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, and preparation and uses thereof
DE602005024677D1 (de) * 2004-04-22 2010-12-23 Memory Pharm Corp Indole, 1h-indazole, 1,2-benzisoxazole, 1,2-benzoisothiazole, deren herstellung und verwendungen
RU2386633C2 (ru) * 2004-05-07 2010-04-20 Мемори Фармасьютиклз Корпорейшн 1h-индазолы, бензотиазолы, 1, 2-бензоизоксазолы, 1, 2-бензоизотиазолы и хромоны и их получение и применения
JP2008525464A (ja) * 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−７ニコチン性受容体リガンド並びにその製造及び使用
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3687080T2 (de) * 1985-04-27 1993-03-25 Beecham Group Plc Azabicyclononyl-indazol-carboxamid mit 5-ht-antagonistischer wirkung.

Also Published As

Publication number Publication date
WO1989004660A1 (en) 1989-06-01
JPH02502185A (ja) 1990-07-19
AU616706B2 (en) 1991-11-07
DK345889D0 (da) 1989-07-12
DK345889A (da) 1989-07-12
EP0340270A1 (de) 1989-11-08
DE3872872T2 (de) 1993-02-04
DE3872872D1 (de) 1992-08-20
EP0340270B1 (de) 1992-07-15
KR890701099A (ko) 1989-12-19
AU2626488A (en) 1989-06-14
US5098909A (en) 1992-03-24

Similar Documents

Publication Publication Date Title
DE3872872D1 (de) 5-ht3-rezeptor-antagonisten zur behandlung von husten und bronchokonstriktion.
DK46789D0 (da) 3-indolpyrodruesyrederivater og farmaceutisk anvendelse deraf
DE69925024D1 (de) Verwendung von eph-rezeptor-antagonisten und agonisten zur behandlung von vaskulären krankheiten
PT98710A (pt) Processo de preparacao de compostos de indolilo substituidos e de composicoes farmaceuticas que os contem
DE69528475D1 (de) Verwendung von serotonin-antagonisten (5ht3) zur behandlung von fibromyalgie
ATE198830T1 (de) Verwendung von nikotinanalogen zur behandlung von degenerativen erkrankungen des nervensystems
NO2015027I1 (no) Mepolizumab
DE69805973D1 (de) Behandlung von herzrythmusstörungen durch hemmung einer multifunktionalen calcium/calmodulin-abhängigen protein kinase
DE69017302D1 (de) Zentrale Cholecystokinin-Antagonisten zur Behandlung von psychiatrischen Krankheiten.
DE3650647D1 (de) Arzneimittel zur Behandlung von Anxietas
IL83687A0 (de)
PT83535A (de) Verfahren zur behandlung von atherosklerose thrombose und der peripheren gefaesskrankheit
DE69316013D1 (de) Verwendung von phosphinate zur behandlung der osteoporose
ATE224719T1 (de) Phosphatidsäure enthaltende zusammensetzungen
BR9508406A (pt) Uso de um composto e método para o tratamento e/ou profilaxia em mamíferos
ATE127021T1 (de) Immunstimulierendes arzneimittel, das polare glycopeptidolipide von mycobakterium-chelonae enthält.
DE69207698D1 (de) Arylalkylester der 4,5-dihydoxy-9,10-dihydro-9,10-dioxo-2-anthracencarbonsäure und deren therapeutische verwendung
DE69023006D1 (de) Verfahren zur behandlung von thrombocytopenie und dafür geeignete pharmazeutische zusammensetzungen.
ATE222768T1 (de) Ctla-8 in kombination mit g-csf oder mit g-csf und il-6, und verwendung vom ctla-8 zur behandlung von infektionen
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
ATE80998T1 (de) Verwendung von nalmefen zur herstellung eines arzneimittels zur behandlung der schaedigung des zentralnervensystems.
ATE221068T1 (de) Anellierte beta-carboline
DD234236A1 (de) Vorrichtung zur abscheidung und thermischen behandlung von feinkoernigem gut
ATE95061T1 (de) Schmiermittelzubereitung zur behandlung von rheuma.

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee